Galectin Therapeutics Inc
GALT3.590USD
-0.060-1.64%
收盤 08/04, 16:00（美東）報價延遲15分鐘
227.22M總市值
虧損本益比TTM
關於 Galectin Therapeutics Inc 公司
Galectin Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，致力於開發新型療法，改善慢性肝病和癌症患者的生活。該公司的候選藥物基於其針對半乳糖凝集素蛋白的方法，半乳糖凝集素蛋白是生物和病理功能的關鍵介質。該公司的主要藥物 belapectin 是一種基於碳水化合物的藥物，可抑制半乳糖凝集素-3 蛋白，該蛋白直接參與多種炎症、纖維化和惡性疾病，美國食品藥品管理局已授予其快速通道資格。主要開發項目是代謝功能障礙相關脂肪性肝炎 (MASH，以前稱爲非酒精性脂肪性肝炎或 NASH) 伴有肝硬化，這是 MASH 相關纖維化的最晚期形式。該公司的其他開發項目是治療晚期頭頸癌和其他惡性腫瘤的聯合免疫療法。
公司簡介
公司代碼GALT
公司名稱Galectin Therapeutics Inc
上市日期Sep 04, 2002
CEOMr. Joel Lewis, CPA
員工數量15
證券類型Ordinary Share
年結日Sep 04
公司地址Suite 240
城市NORCROSS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編30071
電話16786203186
網址https://galectintherapeutics.com/
公司代碼GALT
上市日期Sep 04, 2002
CEOMr. Joel Lewis, CPA
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Dr. Khurram Jamil
Dr. Khurram Jamil
Chief Medical Officer
Chief Medical Officer
60.00K
-9.57%
Dr. Harold H. Shlevin, M.D., Ph.D.
Dr. Harold H. Shlevin, M.D., Ph.D.
Independent Director
Independent Director
15.21K
--
Dr. Benjamin S. Carson, Sr.
Dr. Benjamin S. Carson, Sr.
Director
Director
--
--
Ms. Elissa J. Schwartz, Ph.D.
Ms. Elissa J. Schwartz, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
持股股東
持股股東
佔比
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
股東類型
持股股東
佔比
Individual Investor
21.60%
Investment Advisor
12.44%
Corporation
9.36%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.20%
Bank and Trust
0.17%
Hedge Fund
0.03%
Pension Fund
0.02%
Venture Capital
0.02%
Other
53.56%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
173
29.39M
46.46%
-903.45K
2025Q1
175
29.27M
46.24%
-1.01M
2024Q4
167
29.61M
47.52%
-69.18K
2024Q3
148
29.06M
46.85%
-523.51K
2024Q2
138
28.80M
46.46%
+1.25M
2024Q1
119
26.89M
43.43%
-139.12K
2023Q4
120
26.57M
43.67%
-339.82K
2023Q3
131
28.59M
47.99%
+3.27M
2023Q2
140
24.60M
41.36%
-1.20M
2023Q1
165
24.44M
41.11%
-1.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Uihlein (Richard E)
10.34M
16.34%
--
--
Feb 28, 2025
10X Fund, L.P.
5.92M
9.36%
--
--
Feb 28, 2025
The Vanguard Group, Inc.
2.19M
3.46%
+54.90K
+2.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.34M
2.11%
-201.81K
-13.12%
Mar 31, 2025
Osaic Holdings, Inc.
1.22M
1.93%
+42.88K
+3.63%
Mar 31, 2025
Czirr (James C)
1.09M
1.72%
+323.13K
+42.20%
Jun 06, 2025
Lewis (Joel)
930.30K
1.47%
-56.42K
-5.72%
Mar 03, 2025
Geode Capital Management, L.L.C.
852.71K
1.35%
-17.88K
-2.05%
Mar 31, 2025
Eldred (Kary N.)
499.63K
0.79%
--
--
Feb 28, 2025
Freeman (Kevin D)
462.01K
0.73%
-220.37K
-32.29%
Feb 28, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Fidelity Nasdaq Composite Index ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
